Derin Karacabeyli

Derin Karacabeyli

Auto-generated profile, based on publicly available information

Derin Karacabeyli

Experimental Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2018 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
DKD. Karacabeyli
D. Karacabeyli
SAS. Allender
S. Allender
SPS. Pinkney
S. Pinkney
SAShazhan Amed
Shazhan Amed

1 October 2025 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
DKDerin Karacabeyli
Derin Karacabeyli
DLDiane Lacaille
Diane Lacaille

8 August 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DKDerin Karacabeyli
Derin Karacabeyli
DLDiane Lacaille
Diane Lacaille
NLNa Lu
Na Lu
NMNatalie McCormick
Natalie McCormick
HXHui Xie
Hui Xie
JAJ. Antonio Aviña-Zubieta
J. Antonio Aviña-Zubieta
Objective: To assess the risk of all-cause mortality and major adverse cardiovascular events (MACE) in patients with immune-mediated inflammatory diseases (IMIDs) and type 2 diabetes newly initiating glucagon-like peptide-1 receptor agonists (GLP-1-RAs) versus dipeptidyl peptidase-4 inhibitors (DPP-4is). Methods: We performed a population-based cohort study using administrative health data from British Columbia. Patients with an IMID (i.e., rheumatoid arthritis, psoriatic disease, ankylosing spondylitis, inflammatory bowel disease, or a systemic autoimmune rheumatic disease) and type 2 diabetes who newly initiated a GLP-1-RA or DPP-4i between January 1, 2010, and December 31, 2021 were identified using ICD-9/10 codes. The primary outcome was all-cause mortality. Secondary outcomes included MACE and its components (i.e., cardiovascular death, myocardial infarction, and ischemic stroke). Cox proportional hazard regressions were used with propensity score overlap weighting. The analysis was repeated in age- and sex-matched adults without IMIDs. Results: We identified 10,855 adults with IMIDs and type 2 diabetes who newly initiated a GLP-1-RA or DPP-4i. All-cause mortality rate was lower among initiators of GLP-1-RAs compared to initiators of DPP-4is, with a weighted hazard ratio (HR) of 0.48 (95% confidence interval [CI], 0.31–0.75) and rate difference (RD) of -9.4 (95% CI, -16.0 to -2.7) per 1000 person-years. Rate of MACE was also lower with GLP-1-RA exposure (HR 0.66 [0.50–0.88], RD -10.5 [-20.4 to -0.8]). Effect sizes were similar in adults without IMIDs. Conclusion: In patients with IMIDs and type 2 diabetes, GLP-1-RA exposure is associated with a lower risk of all-cause mortality and MACE compared to a cardioneutral active comparator.

24 February 2026 in Arthritis & Rheumatology
Verified
Journal Article
Open access
DKDerin Karacabeyli
Derin Karacabeyli
DLDiane Lacaille
Diane Lacaille
NLNa Lu
Na Lu
HXHui Xie
Hui Xie
JAJ. Antonio Aviña‐Zubieta
J. Antonio Aviña‐Zubieta
Objective: Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs or SGLT2i versus a weight‐neutral comparator (dipeptidyl peptidase 4 inhibitors [DPP4i]). Methods: We performed a population‐based cohort study using administrative health data from a Canadian province with universal health care. We included adults with type 2 diabetes (T2D) and no prior ARD initiating a GLP‐1RA, SGLT2i, or DPP4i between January 1, 2014, and December 31, 2022. Incident ARD cases, including rheumatoid arthritis, psoriatic disease, axial spondyloarthritis, and systemic ARDs (SARDs; systemic lupus erythematosus, systemic sclerosis, Sjögren disease, idiopathic inflammatory myopathies, and systemic vasculitides), were identified using validated algorithms. Propensity score (PS) weighting was used to balance cohorts at treatment initiation. Then hazard ratios (HRs) were estimated using Cox regression. Results: Among 229,300 adults, 49,514 initiated GLP‐1RAs, 101,925 initiated SGLT2i, and 77,861 initiated DPP4i. After PS weighting, ARD incidence per 10,000 person‐years was 29.1 (95% confidence interval [CI] 23.5–35.5) with GLP‐1RAs, 24.4 (95% CI 19.8–29.7) with SGLT2i, and 27.3 (95% CI 22.1–33.4) with DPP4i. Mean follow‐up was 1.3 to 1.6 years. Relative to DPP4i, adjusted HRs (aHRs) of ARD were 1.04 (95% CI 0.81–1.33) with GLP‐1RAs and 0.93 (95% CI 0.75–1.16) with SGLT2i. Risk of SARDs, but not other diseases, was lower with SGLT2i versus DPP4i (aHR 0.51 [95% CI 0.31–0.84]). Conclusion: Neither GLP‐1RA nor SGLT2i treatment was associated with increased or decreased ARD risk versus DPP4i in adults with T2D; however, SGLT2i use was associated with significantly lower risk of SARDs, warranting further study. image

31 January 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
DKDerin Karacabeyli
Derin Karacabeyli
KSKam Shojania
Kam Shojania
NDNatasha Dehghan
Natasha Dehghan
DLDiane Lacaille
Diane Lacaille

30 March 2026 in Rheumatology
Verified
Journal Article
Open access
PDF file
DKDerin Karacabeyli
Derin Karacabeyli
DLDiane Lacaille
Diane Lacaille
Cardiovascular diseases are the leading cause of premature death in many autoimmune rheumatic diseases (ARDs). Landmark randomized controlled trials in diabetes and obesity have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) have cardiovascular–kidney–metabolic benefits. Observational studies assessing GLP-1RAs in ARDs, including RA and SLE, have found reductions in risk of cardiovascular events similar to those reported in broader populations. GLP-1RAs likely exert their cardioprotective effects through direct and indirect mechanisms. GLP-1RAs treat type 2 diabetes and obesity, two important cardiovascular risk factors. They lower lipid levels by mitigating post-prandial hyperlipidaemia and reduce blood pressure by dampening carotid body–mediated sympathetic excitation. GLP-1RAs have anti-atherogenic and anti-inflammatory effects in mice. They attenuate T cell–mediated inflammation directly by activating GLP-1 receptors on gut intraepithelial lymphocytes, and myeloid cell-mediated inflammation indirectly by activating central neuronal GLP-1 receptors. While knowledge gaps remain, existing evidence supports a cardioprotective role for GLP-1RAs in ARDs.